DTRM-505

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameDTRM-505
Drug Alias NamemTOR inhibitor (DTRM BIOPHARMA)DTRM-505
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsSerine/threonine-protein kinase mTOR inhibitors
TargetsSerine/threonine-protein kinase mTORTyrosine-protein kinase BTK
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesDTRM Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDTRM Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A